UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.587

Sortiert nach

Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer

Cancers, 2022-01, Vol.14 (2), p.294

2022

Volltextzugriff (PDF)

Cellular senescence in cancer: from mechanisms to detection

Molecular oncology, 2021-10, Vol.15 (10), p.2634-2671

2021

Volltextzugriff (PDF)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

The New England journal of medicine, 2023-01, Vol.388 (1), p.44-54

2023

Volltextzugriff (PDF)

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1691-1701

2019

Volltextzugriff (PDF)

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Cancer treatment reviews, 2020-03, Vol.84, p.101974-101974, Article 101974

2020

Volltextzugriff (PDF)

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Annals of oncology, 2018-11, Vol.29 (11), p.2214-2222

2018

Volltextzugriff (PDF)

Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes

International journal of cancer, 2022-08, Vol.151 (3), p.372-380

2022

Volltextzugriff (PDF)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Cancer medicine (Malden, MA), 2022-07, Vol.11 (13), p.2541-2549

2022

Volltextzugriff (PDF)

Prospective study of oral microbiome and colorectal cancer risk in low‐income and African American populations

International journal of cancer, 2019-05, Vol.144 (10), p.2381-2389

2019

Volltextzugriff (PDF)

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients

Clinical cancer research, 2018-07, Vol.24 (13), p.3097-3107

2018

Volltextzugriff (PDF)

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Journal of clinical oncology, 2012-03, Vol.30 (8), p.863-870

2012

Volltextzugriff (PDF)

Downregulation of HDAC9 by the ketone metabolite β‐hydroxybutyrate suppresses vascular calcification

The Journal of pathology, 2022-11, Vol.258 (3), p.213-226

2022

Volltextzugriff (PDF)

Racial disparities in mortality for patients with prostate cancer after radical prostatectomy

Cancer, 2021-05, Vol.127 (9), p.1517-1528

2021

Volltextzugriff (PDF)

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

The lancet oncology, 2014-12, Vol.15 (13), p.1433-1441

2014

Volltextzugriff (PDF)

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

The lancet oncology, 2018-12, Vol.19 (12), p.1654-1667

2018

Volltextzugriff (PDF)

Drug‐target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk

Molecular carcinogenesis, 2024-05, Vol.63 (5), p.849-858

2024

Volltextzugriff (PDF)

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable

Lung cancer (Amsterdam, Netherlands), 2017-01, Vol.103, p.27-37

2017

Volltextzugriff (PDF)

Nut consumption in association with overall mortality and recurrence/disease‐specific mortality among long‐term breast cancer survivors

International journal of cancer, 2022-02, Vol.150 (4), p.572-579

2022

Volltextzugriff (PDF)

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

Critical reviews in oncology/hematology, 2012-09, Vol.83 (3), p.407-421

Ou, Sai-Hong Ignatius

2012

Volltextzugriff (PDF)

Prospective study of oral microbiome and gastric cancer risk among Asian, African American and European American populations

International journal of cancer, 2022-03, Vol.150 (6), p.916-927

2022

Volltextzugriff (PDF)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2015-12, Vol.10 (12), p.1670-1674

2015

Volltextzugriff (PDF)

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Journal of clinical oncology, 2015-06, Vol.33 (17), p.1881-1888

2015

Volltextzugriff (PDF)

Crizotinib for the Treatment of ALK‐Rearranged Non‐Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

The oncologist (Dayton, Ohio), 2012-11, Vol.17 (11), p.1351-1375

2012

Volltextzugriff (PDF)

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

Lung cancer (Amsterdam, Netherlands), 2019-07, Vol.133, p.96-102

2019

Volltextzugriff (PDF)

1 – 25 von 2.587

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.240)
Mit Volltextzugriff
(2.424)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Frontiers In Oncology
(124)
Cancer Epidemiology, Biomarkers & Prevention
(94)
Journal Of Thoracic Oncology
(75)
Oncotarget
(75)
International Journal Of Cancer
(74)
Molecular Medicine Reports
(73)
Oncologie
(69)
Lung Cancer
(56)
Breast Cancer Research And Treatment
(54)
Bmc Cancer
(51)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(23)

Menü

Weitere Dienste

Einstellungen

Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer

Cellular senescence in cancer: from mechanisms to detection

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Prospective study of oral microbiome and colorectal cancer risk in low‐income and African American populations

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Downregulation of HDAC9 by the ketone metabolite β‐hydroxybutyrate suppresses vascular calcification

Racial disparities in mortality for patients with prostate cancer after radical prostatectomy

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Drug‐target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable

Nut consumption in association with overall mortality and recurrence/disease‐specific mortality among long‐term breast cancer survivors

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

Prospective study of oral microbiome and gastric cancer risk among Asian, African American and European American populations

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Crizotinib for the Treatment of ALK‐Rearranged Non‐Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

Aktive Filter

Suchergebnisse filtern